KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Account Payables (2017 - 2025)

Pacira BioSciences (PCRX) has 11 years of Change in Account Payables data on record, last reported at -$2.9 million in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 801.23% year-over-year to -$2.9 million; the TTM value through Dec 2025 reached -$5.6 million, down 281.52%, while the annual FY2025 figure was -$5.6 million, 281.52% down from the prior year.
  • Change in Account Payables reached -$2.9 million in Q4 2025 per PCRX's latest filing, up from -$12.0 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $9.7 million in Q2 2024 and bottomed at -$12.0 million in Q3 2025.
  • Average Change in Account Payables over 5 years is -$279400.0, with a median of -$451000.0 recorded in 2022.
  • Peak YoY movement for Change in Account Payables: soared 932.94% in 2023, then crashed 1985.87% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at -$9.4 million in 2021, then skyrocketed by 116.86% to $1.6 million in 2022, then tumbled by 167.38% to -$1.1 million in 2023, then skyrocketed by 69.68% to -$325000.0 in 2024, then crashed by 801.23% to -$2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$2.9 million in Q4 2025, -$12.0 million in Q3 2025, and $6.9 million in Q2 2025.